ONCO Stock Quote Price and Forecast

ONCO

Onconetix Inc

• Price Momentum

  ONCO is trading near the bottom of its 52-week range and below its 200-day simple moving average.

• Price change

  The price of ONCO shares has decreased $0.02 since the market last closed. This is a 2.47% drop.

• Closed at $0.65.

  The stock has since dropped $0.01 in after-hours trading.

Onconetix, Inc. is a commercial stage biotechnology company, which engages in the research, development and commercialization of proprietary therapeutics, diagnostics and services for clinicians and patients for oncology. The company was founded in October 2018 and is headquartered in Cincinnati, OH.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

• Market cap: $2.63M

  A market capitalization up to $300 million places ONCO in the micro-capitalization category.

Ad Feedback

Smart score

Aug 06, 2026 8:30am ET Onconetix Acquisition Target Realbotix Secures Agreement for Humanoid Robot Appearance on Emmy Award-Winning Streaming Series by GlobeNewswire Aug 05, 2026 8:30am ET Onconetix Announces Appointment of Ralph Schiess, PhD to Board of Directors of Proteomedix AG by GlobeNewswire Jul 07, 2026 9:00am ET Onconetix Highlights Realbotix Partnership with Bloom Services to Launch UK Pilot Using Humanoid Robots to Combat Elderly Social Isolation by GlobeNewswire Jun 24, 2026 8:30am ET Onconetix Highlights Realbotix’s Launch of Humanoid Robot and AI Teachers Assistant Pilot Program in New York State School District by GlobeNewswire May 19, 2026 8:00am ET Onconetix, Inc. Announces 1-for-10 Reverse Stock Split by GlobeNewswire May 13, 2026 9:25am ET Onconetix Reports Q1 2026 Progress at Proteomedix AG, Including Two New Peer-Reviewed Publications and Initiation of U.S. Validation Study by GlobeNewswire Apr 09, 2026 8:30am ET Onconetix Highlights Realbotix's Launch of Vinci AI Vision System with Delivery of First Vinci-Equipped Humanoid Robot to Ericsson by GlobeNewswire Apr 02, 2026 8:30am ET Onconetix Highlights Realbotix AI Humanoid Robot Delivery Update by GlobeNewswire Mar 31, 2026 8:30am ET Onconetix Appoints David White as Chief Executive Officer and Sammy Dorf as Member of the Board of Directors by GlobeNewswire Mar 25, 2026 12:47pm ET Onconetix Highlights Realbotix’s Role in Ericsson’s World-First 6G Trial Demonstration by GlobeNewswire Mar 23, 2026 8:30am ET Onconetix, Inc. Announces 1-for-5 Reverse Stock Split by GlobeNewswire Feb 12, 2026 8:00am ET Onconetix to Acquire Realbotix LLC, USA-based, AI-Powered Humanoid Robotics Company by GlobeNewswire Sep 26, 2025 8:30am ET Onconetix Announces Financing Through a $12.9 Million Private Placement of Series D Preferred Stock and Warrants, Termination of Merger Agreement with Ocuvex, Inc. and Settlement of $8.8 Million Debt with Veru, Inc. by GlobeNewswire Sep 26, 2025 8:15am ET Joint Press Release: Onconetix and Ocuvex Announce Mutual Termination of Merger Agreement by GlobeNewswire Sep 22, 2025 8:00am ET Onconetix announces its subsidiary, Proteomedix, licenses manufacturing IP to Immunovia enabling them to independently produce key reagents for their pancreatic cancer test PancreaSureTM by GlobeNewswire Jul 16, 2025 8:17am ET Onconetix and Ocuvex Therapeutics announce execution of definitive merger agreement by GlobeNewswire Jun 16, 2025 8:22am ET Onconetix, Inc. Announces Positive Decision by Nasdaq Hearings Panel by GlobeNewswire Jun 11, 2025 11:30am ET Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders by GlobeNewswire May 22, 2025 4:50pm ET Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq by GlobeNewswire Apr 30, 2025 6:13pm ET Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq by GlobeNewswire Apr 08, 2025 8:30am ET Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc. by GlobeNewswire Mar 24, 2025 8:45am ET Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort by GlobeNewswire Mar 19, 2025 8:00am ET Onconetix Announces New Clinical Data for its Innovative Prostate Cancer Test Proclarix Accepted for Presentation at 2025 European Association of Urology Congress by GlobeNewswire Dec 12, 2024 10:00pm ET Onconetix, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q and Subsequent Filing by GlobeNewswire

• Total revenue: $815.37K (1Y), $17.12K (Q2)

  Total Revenue decreased 67.7% since last year and decreased 20.21% since last quarter.

• Net income: -$14.03M (1Y), -$2.87M (Q2)

  Net Income increased 76.09% since last year and increased 31.97% since last quarter.

• Earnings per share: -$828.15 (1Y), -$1.28 (Q2)

  EPS increased 99.09% since last year and increased 98.09% since last quarter.

Ad Feedback

analyst rating

• buy
• hold
• sell

We're sorry, but this
information is
temporarily unavailable.

• How competitors are chosen

  ONCO's competitors are included in the Health Technology sector and Pharmaceuticals: Major group

• Market cap: $2.63M

  A market capitalization up to $300 million places ONCO in the micro-capitalization category.

Latest investing news

• Bond market takes a breather after surprise move by Treasury Department

• Global bond markets are getting hammered. Here’s why that could make your life more expensive

• ‘Brazen act of self-dealing.’ Lawmakers, watchdogs alarmed after Trump regulators let Trump firm start a bank

• The S&P 500 is back at a record high and the Dow just hit 54,000

Scan the QR code to download the CNN app on Google Play.

Scan the QR code to download the CNN app from the Apple Store.